Business
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Wa'el Hashad Wa'el Hashad, CEO, Longeveron Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Wa'el Hashad","length":16,"tagName":"p"},{"type":"image","alt":"Wa'el Hashad, CEO, Longeveron","displaySize":"","headline":null,"caption":"Wa'el Hashad, CEO, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":907,"height":1280,"url":"https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hZLnIg4nVu41VQzOxrCMhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzNTU7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963","width":907,"height":1280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NHV_NdOUWrkCMC9duEKhdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4MTQ7aD0yNTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963","width":907,"height":1280}}},{"type":"list","items":[{"val":[{"type":"text","content":"Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indication","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":256,"olType":false},{"type":"text","content":"MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.","length":392,"tagName":"p"},{"type":"text","content":"“We’re proud to be a Semifinalist team of XPRIZE He...